02Aug
FDA Issues Cannabidiol Marketing Warning as Congressional Pressure for Action Continues
Following through with its promise to take enforcement actions against companies marketing cannabis-derived products that could put consumers at risk, the Food and Drug Administration (FDA) recently issued a warning letter to Curaleaf Inc., a...
By:
Wilson Sonsini Goodrich & Rosati
Related
Frazier Healthcare Partners has acquired a 50% stake in CSafe Global from Thomas H. Lee Partners (TH...
Read More >
In 2018, California passed a law that greatly expanded sexual harassment training requirements for e...
Read More >
In the Matter of Giora Neeman v Town of Warwick, __AD3d__, 2020 NY Slip Op 03112, the Second Departm...
Read More >
Employers are rightfully concerned about what, if anything, they should be doing to respond to the c...
Read More >
‘No-poach’ agreements between businesses not to compete with each other for employees have long be...
Read More >
Work was quiet on a particular summer afternoon way back when, when I was an associate in a big law ...
Read More >